• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Treatment of Enterohemorrhagic E. coli (EHEC) infection and Hemolytic Uremic Syndrome (HUS)

tetano

Editor, Senior Moderator
Verotoxigenic E. coli (VTEC) are a specialised group of E.

coli, that cause severe colonic disease and renal failure. Their pathogenicity derives from virulence factors which enable the bacteria to colonise the colon and deliver extremely powerful toxins known as verotoxins (VT) or Shiga toxins (Stx) to the systemic circulation.

The recent devastating E. coli O104:H4 epidemic in Europe has shown how helpless we are in terms of offering effective therapies.

By examining the sources and distribution of these bacteria, and how they cause disease , we will be in better shape to prevent and treat the inevitable future cases of sporadic disease and victims of common-source outbreaks. Due to the complexity of pathogenesis, it is likely a multi-targeted approach is warranted.

Developments in terms these treatments are discussed.See related article: http://www.biomedcentral.com/1741-7015/10/11

Author: Paul N GoldwaterKarl A Bettelheim
Credits/Source: BMC Medicine 2012, 10:12



Published on: 2012-02-02

http://7thspace.com/headlines/40495...ection_and_hemolytic_uremic_syndrome_hus.html
 
Back
Top